Kalaris Therapeutics (KLRS) Assets (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Assets of $109.8 million for Q1 2026, up 6.51% year-over-year from $103.1 million in Q1 2025, and down 9.8% quarter-over-quarter from $121.7 million in Q4 2025.
Kalaris Therapeutics (KLRS) Assets (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Assets history runs 8 years deep, the most recent figure standing at $109.8 million for Q1 2026.
- In Q1 2026, Assets rose 6.51% year-over-year to $109.8 million; the TTM figure through Mar 2026 stood at $109.8 million (up 6.51% YoY), while the FY2025 annual figure was $121.7 million, up 1875.59% from the prior year.
- Assets for Q1 2026 stood at $109.8 million, down from $121.7 million in the prior quarter.
- The five-year high for Assets was $293.7 million in Q3 2022, with the low at $6.2 million in Q4 2024.
- The 5-year median for Assets is $144.1 million (2024), against an average of $169.4 million.
- The sharpest annual moves came in 2024 and 2025: Assets plunged 96.77% in 2024, then surged 1875.59% in 2025.
- Kalaris Therapeutics' Assets stood at $277.1 million in 2022, then slumped by 31.14% to $190.8 million in 2023, then slumped by 96.77% to $6.2 million in 2024, then soared by 1875.59% to $121.7 million in 2025, then declined by 9.8% to $109.8 million in 2026.
- Business Quant data shows KLRS's Assets at $109.8 million in Q1 2026, $121.7 million in Q4 2025, and $81.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 19.82 Bn |
| 10 | Kalaris Therapeutics | 96.14 Mn | 96.14 Mn | - | 99.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 99.54 Mn |
| Mar 31, 2026 | 109.81 Mn |
| Dec 31, 2025 | 121.74 Mn |
| Sep 30, 2025 | 81.18 Mn |
| Jun 30, 2025 | 92.84 Mn |
| Mar 31, 2025 | 103.09 Mn |
| Dec 31, 2024 | 6.16 Mn |
| Sep 30, 2024 | 122.53 Mn |
| Jun 30, 2024 | 130.99 Mn |
| Mar 31, 2024 | 144.14 Mn |
| Dec 31, 2023 | 190.80 Mn |
| Sep 30, 2023 | 248.31 Mn |
| Jun 30, 2023 | 282.69 Mn |
| Mar 31, 2023 | 244.04 Mn |
| Dec 31, 2022 | 277.08 Mn |
| Sep 30, 2022 | 293.70 Mn |
| Jun 30, 2022 | 200.00 Mn |
| Mar 31, 2022 | 231.09 Mn |
| Dec 31, 2021 | 286.59 Mn |
| Sep 30, 2021 | 316.53 Mn |